The prevalence of metabolic dysfunction–associated steatotic liver disease, chronic kidney disease, and obstructive sleep ...

Drinking sugar-sweetened beverages may increase your risk of heart disease. These drinks are easy to overconsume, and they ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

The most well known GLP-1 medication is Ozempic, though in Australia it is only approved for the management of Type 2 ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...

but this trial is the first to assess tirzepatide's impact on kidney and cardiovascular outcomes in people with obesity, chronic kidney disease and HFpEF, a triad of conditions estimated to affect ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

Rising rates of heart disease are claiming more lives each year, and researchers now believe a lesser-known body measure may offer clues about your future heart health. In recent findings from a large ...

New York’s reputation as a trailblazer for health equity is in danger. We must ensure equity in obesity treatment.

A research team funded by the National Institutes of Health (NIH) uncovered higher rates of heart disease and worse heart health affecting adults living in rural communities compared to urban areas ...